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Introduction
Infections caused by carbapenem-resistant Entero-
bacterales (CRE) are a major clinical challenge and 
a  public health problem (WHO 2017). According to 
the 2019 report of the Centers for Disease Control and 
Prevention (CDC), CRE can cause 13,100 infections 
and 1,100 deaths per year in the USA (CDC 2019). The 
resistance to carbapenems in Enterobacterales is mainly 
associated with the production of different classes of 
carbapenemases (Nordmann et al. 2012).
Horizontal transfer of carbapenemase coding genes 
through mobile genetic elements such as plasmids and 
transposons between Gram-negative microorganisms 
is responsible for the rapid increase of carbapenemase-
producing CRE (CP-CRE) isolates. Carbapenemases 
can hydrolyze not only carbapenems but also most 
other β-lactam antibiotics. There is often coexistence 
of additional resistance mechanisms to other antibiotic 
classes (e.g., fluoroquinolones and aminoglycosides) 
in CP-CRE isolates (van Duin and Doi 2017). It leads 
to very few treatment options available against these 
organisms (Nordmann et al. 2012; van Duin and Doi 
2017). However, a few newly commercialized antibio-
tics (e.g., ceftazidime/avibactam and meropenem/
vaborbactam) have been used for the treatment of 
Klebsiella pneumoniae carbapenemase (KPC) produc-
ers recently, but failed to treat metallo-β-lactamase 
(MBL) producers (King et al. 2017; Bassetti et al. 2018; 
Pfaller et al. 2018). Therefore, it is crucial to detect and 
differentiate KPC and MBL carbapenemase-producers 
rapidly in individual patients.
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This study was conducted to develop a cheap, rapid, and accu-
rate modified combined-disk test (mCDT) approach to detect 
and differentiate KPC and MBL carbapenemases among clinical 
carbapenem-resistant Enterobacterales (CRE) isolates and simul-
taneously distinguish them from carbapenem-susceptible Entero- 
bacterales (CSE) isolates. A total of 163 CRE and 90 third-gener-
ation cephalosporin-resistant Enterobacterales isolates were tested 
using imipenem and meropenem disks and different concentrations 
of carbapenemase inhibitors. The optimal sensitivity and specificity 
for detecting KPC carbapenemase were 97.2% and 100%, respec-
tively. The sensitivity and specificity for detecting MBL carbapen-
emase were 100% and 100% with imipenem or meropenem and 
carbapenemase inhibitors within six hours. The inhibitory zone 
diameter of 18 mm for imipenem or meropenem disks without 
inhibitor could distinguish CRE from CSE isolates. Therefore, this 
mCDT approach may be a useful tool in clinical laboratories to 
detect CRE isolates and differentiate KPC and MBL producers, 
which is beneficial for patient management and hospital infection 
prevention and control.
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Several carbapenemase detection methods have 
been developed, including carbapenem hydrolysis 
derived methods, such as the modified Hodge test 
(Carvalhaes et al. 2010), modified carbapenem inac-
tivation method (mCIM) (Pierce et al. 2017), Carba 
NP test (Laolerd et al. 2018), matrix-assisted laser 
desorption ionization-time of flight (MALDI-TOF) 
mass spectrometry assay (Papagiannitsis et al. 2015), 
carbapenemase activity inhibition based methods (Li 
et al. 2019), and antibody- (Kieffer et al. 2019) and PCR-
based methods (Cointe et al. 2019). However, modified 
Hodge test, mCIM, Carba NP test, and MALDI-TOF 
assays cannot differentiate KPC and MBL carbapen-
emase, although the latter two methods require only 
about two hours to diagnose (Papagiannitsis et al. 2015; 
Pierce et al. 2017; Laolerd et al. 2018). Although anti-
body- and PCR-based methods can differentiate KPC 
and MBL within two hours, they cannot distinguish 
CRE from carbapenem-susceptible Enterobacterales 
(CSE) isolates when encountering an Enterobacterales 
isolate whose antimicrobial susceptibility is unknown. 
Besides, they are more expensive than other methods 
(Cointe et al. 2019; Kieffer et al. 2019). As a result, all 
of these available methods cannot meet the clinical 
requirements satisfactorily.
KPC and MBL are the most frequently encountered 
carbapenemases among CP-CRE isolates in China, and 
the latter is distributed worldwide (Logan and Wein-
stein 2017). Therefore, in the context, we explored 
a  cheap, rapid, and accurate method to detect and 
characterize KPC and MBL carbapenemases among 
Enterobacterales isolates and to discriminate CRE from 
CSE for providing the basis of choice of antibiotics for 
clinicians to treat CP-CRE infected patients and prevent 
their further spread in medical institutions.
Experimental
Materials and Methods
Bacterial isolates. A total of 253 retrospectively col-
lected between January 2014 and January 2019, non-
duplicate Enterobacterales isolates, including 163 CRE 
isolates and 90 third-generation cephalosporin-resis-
tant Enterobacterales (3GCeRE) isolates from the 
Department of Infectious Diseases and Clinical Micro- 
biology, Beijing Chao-Yang Hospital were included. 
CRE was defined as an isolate non-susceptible to 
imipenem or meropenem (for the bacteria intrinsically 
resistant to imipenem, non-susceptible to meropenem 
other than imipenem is required), with a minimum 
inhibitory concentration (MIC) ≥ 2 µg/ml, or produc-
ing carbapenemase. 3GCeRE was defined as an isolate 
resistant to ceftazidime (MIC ≥ 16 µg/ml), ceftriaxone 
(MIC ≥ 4 µg/ml), and cefotaxime (MIC ≥ 4 µg/ml), but 
susceptible to carbapenems. The MICs were measured 
by the broth microdilution (BMD) method, and the 
interpretative criteria were based on the Clinical and 
Laboratory Standards Institute (CLSI 2019). All the 
isolates were identified by the Vitek MALDI-TOF MS 
(bioMérieux, France).
Molecular detection of carbapenemase genes. 
As previously described, the blaIMP, blaNDM, and blaVIM 
genes were each detected by PCR (Jing et al. 2018). The 
blaNMC, blaSME, blaIMI, blaGES, blaSPM, blaGIM, blaSIM, and 
blaOXA-48-like genes were detected by a single primer set 
(Queenan and Bush 2007). The primers for the blaKPC 
gene used in the study were previously described (Poirel 
et al. 2011), but the PCR was performed by a different 
procedure. Briefly, 12.5 µl of PCR Master Mix (Thermo 
Scientific, USA) was mixed with 2 µl of forward and 
reverse primers and water to a final volume of 23 µl. 
Then, 2 µl of purified DNA template was added to the 
mix. The PCR program consisted of an initial dena-
turation step at 95°C for 5 min, followed by 35 cycles 
of denaturation at 95°C for 30 s, annealing at 55°C for 
30 s, elongation at 72°C for 60 s, and a final extension 
at 72°C for 7 min. All of the primers used in the study 
are listed in Table SI.
The PCR products were sequenced bi-directionally 
using an ABI 3730XL DNA sequencer (Applied Bio-
systems, USA). The gene sequences were compared 
with those in the database located at the NCBI blast 
server (http://blast.ncbi.nlm.nih.gov). A minimum of 
99% sequence identity and 99% coverage threshold was 
deemed to confirm each gene.
Phenotypic detection of KPC and MBL by a modi-
fied combined disk test. Inhibitor solutions of 50 mg/ml 
APB (3-aminophenyl boronic acid hydrochloride, 
Sigma-Aldrich, USA), and 0.5 M EDTA (ethylenedi-
aminetetraacetic acid disodium salt dihydrate, Sigma-
Aldrich, USA) were filtered using a 0.22 µm filter 
membrane (Millipore, Germany), and stored at 4°C 
(Petropoulou et al. 2006; Doi et al. 2008). The modified 
combined disk test (mCDT) was carried out using four 
10-μg imipenem (or meropenem) disks (Oxoid, UK), 
including a disk alone, a disk plus 5 µl (or 10 µl) of APB 
for KPC inhibition, a disk plus 5 µl (or 10 µl) of EDTA 
for MBL inhibition, and a disk plus both APB and EDTA 
for simultaneous inhibition of KPC and MBL (Tsakris 
et al. 2010; Pournaras et al. 2013). The four disks were 
placed onto Mueller-Hinton agar (Becton, Dickinson 
and Company, USA) plates inoculated with bacterial 
suspensions of 2.80 ± 0.15 McFarland optical density. 
The inhibition zones were measured after incubation for 
6 hours at 35 ± 2°C in ambient air. An increase of ≥ 5 mm 
in the inhibition zone diameter of the imipenem (or 
meropenem) disk containing inhibitors (APB, EDTA, 
or both) in comparison to the same disk without the 
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corresponding inhibitor was suggestive of KPC, MBL, or 
both carbapenemases production, respectively. Quality 
control strains included Escherichia coli ATCC 25922, 
Klebsiella pneumoniae ATCC BAA-1705, and Klebsiella 
pneumoniae ATCC BAA-1706.
Statistical analysis. The sensitivity and speci- 
ficity were determined to assess the performance of 
mCDT for the identification and differentiation of car- 
bapenemase using PCR results as a standard. Data 
were analyzed using the VassarStats online software 
(VassarStats.net).
Results
Species distribution and carbapenemase genes. 
One hundred and sixty-three CRE and ninety 3GCeRE 
isolates comprised eight bacterial species: K. pneumo-
niae (n = 141), E. coli (68), Klebsiella aerogenes (n = 14), 
Enterobacter cloacae (n = 13), Proteus mirabilis (n = 5), 
Providencia rettgeri (n = 5), Citrobacter freundii (n = 4), 
and Serratia marcescens (n = 3). The PCR and sequenc-
ing results are shown in Table I. One hundred and 
forty-five CRE isolates were confirmed to be carrying 
carbapenemase genes. Of them, the blaKPC gene was the 
most often discovered carbapenemase gene (n = 107), 
followed by the blaNDM gene in 30 isolates, blaIMP in six 
isolates, and blaOXA-48-like in one isolate, as well as both 
blaKPC and blaNDM in one isolate. The remaining 18 CRE 
isolates and all 3GCeRE isolates were negative for car-
bapenemase genes.
Differentiation of CRE and 3GCeRE isolates. The 
distribution of inhibitory zone diameter (IZD) of the 
imipenem disk alone after six hours of incubation is 
shown in Fig. 1a. The IZDs of all CRE isolates were 
KPC (107) 104 1 0 1 1 0 0 0
MBL (36)
NDM (30) 7 15 1 0 1 4 1 1
IMP (6) 3 0 3 0 0 0 0 0
OXA-48-like (1) 1 0 0 0 0 0 0 0
KPC+NDM (1) 1 0 0 0 0 0 0 0
Non-CP-CRE (18) 8 5 2 3 0 0 0 0
3GCeRE (90) 17 47 7 10 2 1 4 2
Total (253) 141 68 13 14 4 5 5 3
Table I
Species distribution of different carbapenemase types among non-CP-CRE and 3GCeRE isolates.
Kpn – Klebsiella pneumoniae, Eco – Escherichia coli, Ecl – Enterobacter cloacae, Kae – Klebsiella aerogenes,
Cfr – Citrobacter freundii, Pre – Providencia rettgeri, Pmi – Proteus mirabilis, Sma – Serratia marcescens
Category (n)
Species
Kpn Eco Ecl Kae Cfr Pre Pmi Sma
Fig. 1. The inhibitory zone diame-
ter distribution of a) imipenem, 
b) meropenem for Enterobactera-
les isolates tested.
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≤ 18 mm, while all 3GCeRE isolates were ≥ 19 mm. For 
three P. mirabilis the value of IZD was the same and 
equal to 18 mm. Therefore, apart from the three P. mira-
bilis isolates, the imipenem disk alone could distinguish 
CRE from all the other 3GCeRE isolates after six hours 
of incubation.
Compared with imipenem, the distribution of IZDs 
of meropenem disk alone provided a clear distinction 
of CRE and 3GCeRE isolates (Fig. 1b). The IZDs of all 
CRE isolates were ≤ 18 mm, while all 3GCeRE isolates 
were ≥ 20 mm.
Sensitivity and specificity of mCDT. The interpre-
tation of the mCDT results is shown in Fig. 2. When the 
IZD value of imipenem or meropenem disk alone was 
≥ 19 mm, the Enterobacterales isolate was deemed CSE, 
otherwise deemed CRE. Subsequently, an increase of 
≥ 5 mm in the IZD of the imipenem (or meropenem) 
disk containing inhibitors (APB, EDTA, or both) com-
pared to the disk without the corresponding inhibitor is 
deemed as KPC among CRE isolates, MBL, or both car-
bapenemases producer, respectively. At the same time, 
an increase of < 5 mm was deemed as OXA-48-like 
carbapenemase or non-CP-CRE isolate. Fig. 3 shows 
examples of mCDT results.
The accuracies of the mCDT among CRE isolates 
are shown in Table II. For identification of KPC carba-
penemase, the sensitivity of the IPM (imipenem)-5 µl 
APB was 88.8% (95/107), with a specificity of 100% 
IPM-5 µl APB KPC  88.8 (80.9–93.8) 100 (92.0–100)
IPM-5 µl EDTA MBL 100 (88.0–100) 100 (96.3–100)
IPM-10 µl APB KPC  97.2 (91.4–99.3) 100 (92.0–100)
IPM-10 µl EDTA MBL 100 (88.0–100) 100 (96.3–100)
MEM-5 µl APB KPC  48.6 (38.9–58.4) 100 (92.0–100)
MEM-5 µl EDTA MBL 100 (88.0–100) 100 (96.3–100)
MEM-10 µl APB KPC  59.8 (49.9–69.0) 100 (92.0–100)
MEM-10 µl EDTA MBL 100 (88.0–100) 100 (96.3–100)
Table II
Accuracy of detecting KPC or MBL carbapenemases among 163 CRE isolates
under different conditions.
IPM – imipenem, MEM – meropenem, APB – 3-aminophenyl boronic acid hydrochloride,
EDTA – ethylenediaminetetraacetic acid disodium salt dihydrate
Category Carbapenemase
Accuracy
Sensitivity (%), (95% CI) Specificity (%), (95% CI)
Fig. 2. Flow diagram of the mCDT for distinguishing CRE from CSE isolates, and differentiating KPC and/or MBL producers.
A – imipenem disk alone, B – imipenem disk plus 5 µl EDTA, C – imipenem disk plus 10 µl APB
and D – imipenem disk plus 5 µl EDTA and 10 µl APB.
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(56/56). One C. freundii and 11 K. pneumoniae isolates 
were a false negative. Three K. pneumoniae isolates 
were incorrectly identified as non-CP-CRE or OXA-
48-like producers, while the remaining eight isolates 
were incorrectly identified as KPC and MBL pro- 
ducers. The sensitivity of the IPM-10 µl APB was 
97.2% (104/107), with a specificity of 100% (56/56). 
Three K. pneumoniae isolates were incorrectly iden-
tified as both KPC and MBL producers. These three 
organisms gave similar results with IPM-5 µl APB 
group. However, the sensitivities of the MEM (mero-
penem)-5 µl APB and MEM-10 µl APB were 48.6% 
(52/107) and 59.8% (64/107), respectively, with spe-
cificities of 100% (56/56) in both groups. Tiny bacte-
rial colonies were observed for many KPC-producing 
isolates around MEM disk with APB. Therefore, the 
sensitivities for MEM-5 µl APB and MEM-10 µl APB 
groups were much lower than that of IPM with APB 
groups. Fifty and 36 isolates were incorrectly identified 
as non-CP-CRE or OXA-48-like producers, while five 
and seven isolates were incorrectly identified as both 
KPC and MBL producers in MEM-5 µl APB and MEM-
10 µl APB group respectively.
For the identification of MBL carbapenemases, the 
sensitivity of the IPM-5 µl EDTA was 100% (36/36), 
with a specificity of 100% (127/127). The same results 
were obtained for IPM-10 µl EDTA, MEM-5 µl EDTA, 
and MEM-10 µl EDTA groups.
No statistical analysis was performed for this 
type because there was only one isolate that produced 
both KPC and NDM carbapenemases. The isolate was 
correctly identified for all IPM or MEM disks with 
APB + EDTA groups.
Discussion
The current study detected five different genes by 
PCR and sequencing method in 88.9% of CRE isolates 
(n = 163). The results showed that the blaKPC (73.8%) and 
blaNDM (20.7%) genes were most common, followed by 
blaIMP (4.1%), blaOXA-48-like (0.7%), and blaKPC+NDM (0.7%). 
It follows a report of nationwide surveillance of clinical 
CRE isolates in China, which showed 93% of clinical 
isolates (n = 1105) producing carbapenemases, with 
a majority of isolates producing KPC (57%) or NDM 
(31%) carbapenemases (Zhang et al. 2017). Therefore, 
the main carbapenem-resistant mechanism for clini-
cal Enterobacterales isolates is acquiring the blaKPC or 
blaNDM genes in China.
Due to the high morbidity and mortality associated 
with the invasive infection of CP-CRE strains (CDC 
2019), accurate and fast detection and differentiation 
of CP-CRE types are critical in the individual patient. 
It will help the physicians make decisions on appropri-
ate antibiotic treatment and improve prevention and 
control, especially in outbreak situations (Gutiérrez-
Gutiérrez et al. 2017; Livermore et al. 2018; Li et al. 
2019). Although several methods have been proposed 
(Burckhardt and Zimmermann 2011; Findlay et al. 
2015; Bogaerts et al. 2020) they cannot fully meet the 
clinical demands. The mCIM plus EDTA-carbapenem 
inactivation method (eCIM) and CDT require more 
than 20 hours. Besides, mCIM/eCIM could not detect 
MBL carbapenemase when an Enterobacterales iso-
late produced two types of carbapenemases, includ-
ing the MBL carbapenemase (Tsai et al. 2020). While 
Carba NP and MALDI-TOF MS are rapid, it cannot 
Fig. 3. Examples of mCDT showing the inhibitory zone diameters of A, B, C, and D for a) a plate 7, 7, 14,
and 15 mm confirming the KPC-producing isolate, and for b) a plate 9, 17, 8, 18 mm
confirming the MBL-producing isolate.
 A – imipenem disk alone, B – imipenem disk plus 5 µl EDTA, C – imipenem disk plus 10 µl APB 
and D – imipenem disk plus 5 µl EDTA and 10 µl APB.
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differentiate the type of a carbapenemase. In addi-
tion, commercial immunochromatographic assay and 
PCR method require high cost and cannot distinguish 
CRE from CSE.
In recent years, a simplified carbapenem inactiva-
tion method (sCIM) for detecting carbapenemases 
with high accuracy has been established (Jing et al. 
2018; Yamada et al. 2021). Compared to mCIM, it is 
easier to carry out by smearing the test strain onto an 
imipenem/meropenem disk and then placed the disk on 
Mueller-Hinton agar streaked with 0.5 McFarland stand-
ard Escherichia coli ATCC 25922. The result was read 
after overnight incubation. However, similar to mCIM, 
the long incubation time and inability to distinguish the 
type of carbapenemases will limit its widespread use in 
clinical practice.
This study developed the mCDT method because 
APB can inhibit the KPC carbapenemase and EDTA 
can inhibit MBL carbapenemases (Petropoulou et al. 
2006; Doi et al. 2008). A higher initial concentration of 
the bacteria tested will reduce the time to form visible 
bacterial colonies. However, when the initial bacterial 
suspension was set for 3.5 McFarland optical density, the 
inhibitory effect of APB on the KPC carbapenemase was 
significantly reduced for many isolates, and tiny bacte-
rial colonies could be seen around an imipenem disk 
with APB (Fig. S1). Thus, the inoculum was 2.80 ± 0.15 
McFarland optical density (less than 3) to prevent the 
tiny bacterial colonies in this study. The incubation time 
was set for six hours, making it easy to read results due 
to the formation of a clear inhibition zone compared to 
five hours or less. Therefore, it is a facile and inexpen-
sive in-house approach, which requires only six hours 
because the bacteria’s high concentration (2.80 ± 0.15 
McFarland optical density) is inoculated.
The mCDT can be utilized to detect CRE in clini-
cal laboratories and simultaneously differentiate the 
KPC and MBL type of CP-CRE isolates. An overnight 
pure culture of bacteria identified as Enterobacterales 
strains can be used for mCDT in the morning, and the 
result can be acquired after six hours of incubation in 
the afternoon. As a result, this method can shorten the 
turnaround time since it can be carried out simultane-
ously as the antibiotic susceptibility test and acquire 
the results in six hours. It should be noted that an IZD 
of 18 mm as the breakpoint we describe is smaller than 
the IZD of 22 mm for imipenem and meropenem pro-
posed by CLSI to distinguishing CRE from CSE iso-
lates (CLSI 2019). In this study, applying the 18 mm 
breakpoint could detect all CRE strains and exclude 
all 3GCeRE strains for meropenem disk, but the IZDs 
of imipenem disk for three carbapenem-susceptible 
P. mirabilis isolates were 18 mm due to the intrinsic 
imipenem resistance. It is observed for Morganella mor-
ganii, Proteus spp., and Providencia spp. (CDC 2019). 
Therefore, it is better to use a meropenem disk to dis-
tinguish CRE from CSE isolates for those intrinsically 
imipenem-resistant strains.
APB inhibits KPC carbapenemase due to the boro-
nate moiety binding to the catalytic serine side chain; 
thus, forming the covalent adduct and inactivating it 
(Hecker et al. 2015). In the current study, most KPC-
producing isolates could not be detected by meropenem 
but imipenem disk due to tiny bacterial colonies formed 
around a meropenem disk with APB. This result indi-
cates that the covalent adduct still retains a low level 
of catalytic efficiency, and the catalytic efficiency to 
meropenem is higher than that of imipenem. The rea-
son may be that the affinity of the covalent adduct to 
meropenem is higher than that of imipenem.
This study has some limitations. First, the mCDT 
was not suitable for detecting OXA-48-like carbapen-
emases because there is no specific inhibitor against 
OXA-48-like carbapenemases available. Second, this 
study did not include MBL carbapenemases except 
NDM and IMP (e.g. VIM and others). Third, this 
method cannot detect class A carbapenemases except 
KPC (e.g. GES, SME) because they cannot be inhib-
ited by APB (Nordmann et al. 2012). According to the 
report of Lee and Suh (2021), detection of GES by mod-
ified Hodge test (MHT), mCIM, and Rapidec Carba NP 
was also very poor, which is a tricky problem.
Conclusions
In summary, the proposed mCDT that used 10 μl 
APB and 5 μl EDTA as inhibitors enables detection 
and differentiation of KPC and MBL carbapenemase 
types and distinguishes CRE from CSE simultaneously 
within six hours among Enterobacterales isolates. It 
could be a low cost, high accuracy, and easy operational 
approach. While this approach requires validation in 
other laboratories, we believe that the mCDT may be 
useful, especially in low-income countries and regions 
where KPC and MBL carbapenemases are epidemics.
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